Background: Recent hypertension trials have demonstrated the importance of achieving goal blood pressures to reduce the risk of target organ damage. In patients with moderate to severe hypertension, the use of high-dose monotherapy and/or combinations of drugs are necessary to achieve these goals. Fixed-dose combination products may be useful in these patients by reducing the number of daily doses required to control blood pressure. Objective: The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/ benazepril (Lotrel  ; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension. Methods: A total of 75 patients were switched from amlodipine (n = 25), felodipine (n = 25), and nifedipine-GITS (n = 25) to amlodipine/benazepril. Twenty-eight of the 75 patients (37%) were taking either a beta-blocker or a diuretic in addition to the high-dose calcium channel blocker prior to the switch. Blood pressure control, side
Introduction
Recent clinical trials such as the Hypertension Optimal Treatment (HOT) trial and the Captopril Prevention Project (CAPP) indicate that achievement of goal blood pressure reduces target organ damage. 1, 2 In patients with higher elevations of blood pressure, achievement of goal blood pressure often requires the use of high dose monotherapy or the combination of two or more antihypertensive agents. 1, 3 Fixed-dose combination antihypertensive agents represent a therapeutic alternative to high dose monotherapy or to multiple drug combinations in the treatment of hypertension. 4 The fixed-dose combination of amlodipine/ benazepril (Lotrel  ) was the first calcium channel blocker/angiotensin-converting enzyme inhibitor combination marketed in the United States. This combination has been shown to have a superior blood pressure lowering effect compared to its individual drug components with an excellent safety profile. 5 The objective of this study was to evaluate the efficacy, safety, and cost of a therapeutic interchange from high dose amlodipine, felodipine, or nifedipine-GITS therapy to a fixed-dose combination of amlodipine/benazepril in patients with moderate to severe hypertension.
Patients and methods
Patients aged 35 to 70 years without restrictions regarding gender or race were eligible to participate in the trial. Diastolic blood pressure prior to the initiation of any antihypertensive therapy had to be between 95 and 115 mm Hg. Pretreatment systolic blood pressure had to be less than 180 mm Hg. Patients had to be treated with stable doses of amlodipine 10 to 20 mg per day, felodipine 10 to 20 mg per day, or nifedipine-GITS 60 to 120 mg per day for a minimum of 6 months prior to study entry. Patients who were receiving a maximum of one additional antihypertensive agent (restricted to either a thiazide diuretic or a beta-blocker) prior to the initiation of calcium channel blocker therapy could continue that therapy as long as the dose of that drug remained constant throughout the study. Diastolic blood pressure on antihypertensive therapy prior to the switch to amlodipine/benazepril had to have been reduced to р90 mm Hg or had to have decreased by у10 mm Hg from pretreatment values.
Patients with renal (serum creatinine Ͼ2.0 mg/dL) or hepatic dysfunction (serum aminotransferase levels two times greater than the upper limit of normal) were excluded. Patients with unstable angina, myocardial infarction or coronary revascularisation in the 6 months prior to study enrollment were excluded. Patients with symptomatic heart failure, left ventricular dysfunction defined as an ejection fraction р40%, cardiac arrhythmias requiring antiarrhythmic therapy or an implantable cardioverter-defibrillator were excluded. Patients judged to be noncompliant with antihypertensive medication (Ͻ80% prescription refill history in the prior 6 months) were excluded.
Study design
Patients who met eligibility criteria had their calcium channel blocker therapy discontinued without dose tapering. On the day following discontinuation, these patients were started on the amlodipine/ benazepril combination at the 2.5 mg/10 mg dose. Following the switch, patients were seen in the clinic at monthly intervals. If the patient's diastolic blood pressure was Ͼ5 mm Hg higher or if the systolic blood pressure was Ͼ10 mm Hg higher at the first or any subsequent follow-up visit, the dose of amlodipine/benazepril was increased to the 5 mg/10 mg dose and then to the 5 mg/20 mg dose, if necessary. Additional physician office visits were allowed at the discretion of the primary care physician. Laboratory tests or other diagnostic tests were not required by protocol, but were allowed at the discretion of the primary care physician. If doselimiting side effects occurred or if the 5 mg/20 mg dose of amlodipine/benazepril failed to maintain blood pressure, patients were switched back to their original calcium channel blocker. These patients were classified as treatment failures. Patients defined as having a successful switch were required to have three consecutive monthly BP readings on amlodipine/benazepril that were within 5 mm Hg of their last diastolic and systolic BP reading on calcium channel blocker therapy. Patients successfully switched to the fixed-dose combination product were allowed to continue this therapy as maintenance therapy. Patients were followed for one year after the switch to amlodipine/benazepril.
Cost analysis
The cost analysis included direct medical costs incurred by patients who were switched to amlodipine/benazepril. Direct medical costs of the switch included the acquisition cost of the drugs, costs of all clinic and emergency room visits, and laboratory and diagnostic test costs.
Acquisition costs of drugs were based on 2000 PC Price-Chek  (MediSpan Inc; St Louis, MO, USA). 6 Costs for clinic and emergency room visits were $28 and $300, respectively. Laboratory test costs were as follows: electrolytes with renal function, $24; complete blood count, $19; metabolic profile (electrolytes, lipids, renal, hepatic) $38; and 12-lead electrocardiograms were $12. All health care contacts and laboratory/diagnostic tests that occurred in the year following the switch to amlodipine/benazepril were included in the cost analysis.
Results
Seventy-five patients stabilised on amlodipine (n = 25), felodipine (n = 25), or nifedipine-GITS (n = 25) for moderate to severe hypertension were switched from their calcium channel blocker to amlodipine/benazepril (Table 1) . Baseline clinical characteristics and blood pressures were similar among the patients treated with the three different calcium channel blockers. Twenty-eight of the 75 (37%) patients were already taking and continued either a diuretic (n = 10) or a beta-blocker (n = 18) during calcium channel blocker therapy.
Blood pressure response and adverse effects observed during therapy with calcium channel blockers is summarised in Table 2 . Patients switched to the fixed-dose combination product is summarised in Side effects on CCB therapy (n) oedema (10) oedema (12) oedema (15) dizziness (2) rash (3) headache (8) headache (2) headache (2) flushing (4) flushing (1) flushing (1) dizziness (2) weakness (1) dyspepsia (1) dizziness (1) weakness (1) diarrhoea (1) dyspepsia (1) Number of patients reporting one or more side 8 (32%) 11 (44%) 14 (56%) effects on CCB (%) CCB, calcium channel blocker. Table 3 . Mean blood pressure during amlodipine/ benazepril therapy was not significantly different from that observed during baseline calcium channel blocker therapy. A total of 66 of the 75 (88%) patients were successfully switched to fixed-dose amlodipine/benazepril combination therapy. Twentytwo of 25 (88%) patients on amlodipine, 23 of 25 (92%) patients on felodipine, and 21 of 25 (84%)
Journal of Human Hypertension patients on nifedipine-GITS were successfully switched to the amlodipine/benazepril combination. Thirty-three patients required one dose titration and 12 patients required two dose titrations with amlodipine/benazepril to maintain BP control similar to that with calcium channel blocker therapy.
Reasons for treatment failure with amlodipine/ benazepril included failure to maintain blood press-Journal of Human Hypertension (2) 5/20 (3) 5/20 (7) Side effects on AML/BZ therapy (n) cough (3) cough (2) cough (3) oedema (1) oedema (1) oedema (3) headache (2) rash (1) dizziness (2) dizziness (1) dyspepsia (1) weakness (1) rash (1) diarrhoea (1) Patients reporting side effects on AML/BZ (%) 4 (16%) 4 (16%) 5 (20%) AML/BZ, amlodipine/benazepril; BP, blood pressure.
ure control in five patients and the development of dose-limiting side effects in four patients. Treatment failure due to loss of blood pressure control occurred with four patients previously on nifedipine-GITS and in one patient previously on amlodipine. Daily doses of calcium channel blockers prior to switch in patients failing due to loss of blood pressure control included nifedipine-GITS 90 mg/day in three patients, nifedipine-GITS 120 mg/day in one patient, and amlodipine 20 mg/day in one patient.
The overall frequency of side effects was significantly less during amlodipine/benazepril therapy (13/75; 17%) compared to calcium channel blocker therapy (33/75; 44%) (P Ͻ 0.05) ( Tables 1 and 2) . Side effects resulting in discontinuance of amlodipine/benazepril included cough in three patients and maculopapular rash in one patient. Patients failing amlodipine/benazepril therapy were switched back to their original calcium channel blocker. All nine treatment failures were successfully treated to their original blood pressure level after restarting their original calcium channel blocker therapy.
The cost of the therapeutic interchange is summarised for all patients in Table 3 and by the original individual calcium channel blocker in Table 4 . Overall, a $214 per patient per year cost savings was realised. The primary cost advantage of the fixeddose combination product was a $363 per patient per year lower acquisition cost than high-dose calcium channel blocker therapy. This saving was partially offset by the increased costs of clinic and emergency room visits and laboratory and diagnos- tic test costs incurred by patients who were switched to amlodipine/benazepril ( Table 5 ). The total cost savings for all 75 patients switched to amlodipine/benazepril was $16 030. The cost savings of the switch based on the original calcium channel blocker varied widely. In the first year after the switch, cost savings were realised in patients switched from amlodipine ($185 per patient per year) and nifedipine-GITS ($342 per patient per year). However, an excess cost of $26 per patient per year occurred in patients from felodipine to amlodipine/benazepril. This excess cost resulted from the higher acquisition cost of amlodipine/ benazepril compared to felodipine. The cost savings that could be realised in the years after the initial interchange should reflect only differences in acquisition cost between the drugs. The additional costs of ensuring continued efficacy and safety reflected in laboratory and other diagnostic test costs ordered after the switch would not be incurred.
Discussion
It is well established that lower blood pressure is associated with less target organ damage. 7 The JNC-VI treatment guideline recommendations and other recent clinical trial data support achievement of goal blood pressures to reduce the risk of adverse clinical events. 1, 2, 7 Achieving an optimal outcome in hypertensive patients requires achieving a balance between the favourable effects of treatment that lowers blood pressure and the adverse consequences of such treatment. Drug therapy is clearly effective in lowering blood pressure and reducing the risk of stroke and myocardial infarction. 1, 2, 7 Adverse consequences that need to be considered with antihypertensive drug therapy include the side effects of drugs and the costs of using these drugs.
An alternative to using high-dose monotherapy or combinations of drugs is the fixed-dose single-pill antihypertensive combinations. A number of fixeddose combination antihypertensive therapies are currently available in the United States. 7 These combinations have traditionally included a diuretic combined with either a beta-blocker or an angiotensin-converting enzyme inhibitor. [8] [9] [10] In the early 1990s, the first calcium channel blocker/ angiotensin-converting enzyme inhibitor combination (Lotrel  ; amlodipine/benazepril, Novartis) was made available in the United States. This combination provides blood pressure lowering that is superior to amlodipine or benazepril alone with a side effect profile that is similar to or better than either agent alone. 5 This product can be viewed as
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In our study, we evaluated the efficacy, safety, and costs in patients requiring high doses of calcium channel blockers alone or in combination with one other antihypertensive agent who were switched to the fixed-dose combination of amlodipine/ benazepril. We have demonstrated that almost 90% of patients on high dose calcium channel blockers could be successfully switched to amlodipine/ benazepril. In addition to the maintenance of blood pressure control, the incidence of side effects was lower on the fixed-dose combination. A lower incidence of adverse effects may also have potential cost savings (although this was not specifically evaluated in this study). It is important to note that 19 of the 75 (25%) patients in this study were taking calcium channel blocker dosages that were higher than recommended. 7 The total cost savings associated with the therapeutic interchange from calcium channel blockers to amlodipine/benazepril in our 75 patients was $16 030 ($214 per patient) in the first year after the switch.
The average acquisition cost of amlodipine/benazepril was $641 per patient per year compared to $1004 for high dose calcium channel blockers. This $363 difference in acquisition cost was partially offset by switch-related costs including additional clinic visits and laboratory/diagnostic test.
It is of some interest to note that differences in the cost of the switch were influenced by the original calcium channel blockers used. Costs savings were realised in the first year for amlodipine and nifedipine-GITS, but not with felodipine. The reason for this difference in patients receiving felodipine resulted from its lower acquisition cost. The annual average acquisition cost for felodipine was $725 compared to $600 for amlodipine/benazepril. This difference in acquisition cost ($125) was substantially less than that seen with amlodipine ($330) and nifedipine-GITS ($494). It should be pointed out that cost savings in the years subsequent to the switch would reflect only the differences in acquisition cost between the products. The costs of clinic visits and laboratory tests to ensure continued safety and efficacy would not be incurred in subsequent years.
Therapeutic interchange programmes have primarily been used to evaluate the cost-effectiveness of substituting one drug for another in the same therapeutic class. [11] [12] [13] [14] [15] [16] [17] Switching patients from more expensive acquisition cost agents to lower acquisition cost drugs is a strategy that may appear to be economically sound, but should be confirmed by evaluating not only the differences in acquisition cost of the products that are switched, but also the costs involved with switching, which include additional clinic visits and diagnostic or laboratory testing to reconfirm efficacy, the need to titrate the drugs or add additional therapy, and the occurrence of any new side effects that develop following such a product switch. We have established that therapeutic interchange between higher doses of selected calcium channel blockers and the fixed-dose combination product containing amlodipine/benazepril is not only safe and effective, but also cost-effective.
One other potential advantage involved in our therapeutic interchange is the fact that ACE inhibitors have been recently shown to reduce cardiovascular events in patients with complicated hypertension. 18 In contrast, continued concern exists regarding the use of calcium channel blockers, especially high dose therapy, in hypertensive patients. 19 The role of calcium channel blockers in hypertension remains controversial, with data both supporting and condemning their use. 20, 21 The ultimate benefit of one class of antihypertensive therapy over another may not be known until the results of large in-progress mega-trials have been completed. 22, 23 Our study has a number of limitations, including a lack of blinding, the retrospective nature of our data collection for calcium channel blocker therapy, failure to randomise patients to therapy, and the lack of a placebo baseline period prior to initiation of amlodipine/benazepril. This study was primarily designed to reflect the practice employed by managed care organisations who institute therapeutic interchange programmes. Despite these limitations, we believe our results represent a fair estimation of the costs and blood pressure outcomes associated with this type of therapeutic interchange. Our results, however, cannot be extrapolated to other calcium channel blockers or to other classes of antihypertensive agents.
